+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

  • ID: 5024756
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 503 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abeome Corp
  • AusBio Ltd
  • Ergon Pharmaceuticals LLC
  • JW Pharmaceutical Corp
  • Nogra Pharma Ltd
  • RDS2 Solutions Inc
  • MORE
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abeome Corp
  • AusBio Ltd
  • Ergon Pharmaceuticals LLC
  • JW Pharmaceutical Corp
  • Nogra Pharma Ltd
  • RDS2 Solutions Inc
  • MORE
  • Introduction
  • Idiopathic Pulmonary Fibrosis - Overview
  • Idiopathic Pulmonary Fibrosis - Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  • Idiopathic Pulmonary Fibrosis - Drug Profiles
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Au Pty Ltd, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences Inc, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, H1 2020
  • Idiopathic Pulmonary Fibrosis - Pipeline by Amgen Inc, H1 2020
List of Figures
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abeome Corp
  • Accendatech Au Pty Ltd
  • AdAlta Ltd
  • Afimmune Biopharma Ltd
  • Algernon Pharmaceuticals Inc
  • Altavant Sciences Inc
  • Altay Therapeutics Inc
  • Amgen Inc
  • Amplia Therapeutics Ltd
  • AnaMar AB
  • Angion Biomedica Corp
  • Apaxen
  • Aqua Therapeutics Co Ltd
  • Aqualung Therapeutics Corp
  • Ark Biosciences Inc
  • Arroyo BioSciences LLC
  • Asahi Kasei Pharma Corp
  • AstraZeneca Plc
  • Atrapos Therapeutics LLC
  • AusBio Ltd
  • Avalyn Pharma Inc
  • BerGenBio ASA
  • Blade Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bonac Corp
  • BreStem Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Celdara Medical LLC
  • CellCure
  • Certa Therapeutics Pty Ltd
  • Chiesi Farmaceutici SpA
  • Chrysalis Pharma SAS
  • Citryll BV
  • CohBar Inc
  • Collaborations Pharmaceuticals Inc
  • Compugen Ltd
  • CrystalGenomics Inc
  • Daewoong Pharmaceutical Co Ltd
  • EmphyCorp Inc
  • Epitracker Inc
  • Ergon Pharmaceuticals LLC
  • ethris GmbH
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • Galecto Biotech AB
  • GenKyoTex SA
  • Global Blood Therapeutics Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • HEC Pharm Co Ltd
  • iBio Inc
  • Imago Pharmaceuticals Inc
  • Indalo Therapeutics Inc
  • Inventiva
  • iOnctura SA
  • Ionis Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Iterion Therapeutics
  • Jiangsu Hengrui Medicine Co Ltd
  • JW Pharmaceutical Corp
  • Kadmon Corp LLC
  • KBP BioSciences Co Ltd
  • Kither Biotech Srl
  • Kyorin Pharmaceutical Co Ltd
  • Lamellar Biomedical Ltd
  • LifeMax Laboratories Inc
  • Lignamed LLC
  • Liminal BioSciences Inc
  • LTT Bio-Pharma Co Ltd
  • Lung Therapeutics Inc
  • Max Biopharma Inc
  • MDI Therapeutics Inc
  • Medicenna Therapeutics Corp
  • Metagone Biotech Inc
  • Metera Pharmaceuticals Inc
  • Miragen Therapeutics Inc
  • Mission Therapeutics Ltd
  • Moerae Matrix Inc
  • Morphic Holding Inc
  • National Institutes of Pharmaceutical R&D Co Ltd
  • NB Health Laboratory Co Ltd
  • New Amsterdam Sciences Inc
  • Nogra Pharma Ltd
  • Novartis AG
  • Novo Nordisk AS
  • Nuformix Plc
  • Oasis Pharmaceuticals LLC
  • OliX Pharmaceuticals Inc
  • OncoArendi Therapeutics SA
  • Opsidio LLC
  • OptiKira LLC
  • OROX BioSciences Inc
  • Osteoneurogen Inc
  • Palo BioFarma SL
  • Panorama Research Inc
  • Pharmaxis Ltd
  • Pharmicell Co Ltd
  • Pliant Therapeutics Inc
  • Prasan Pharmaceutical Consultants LLC
  • PRISM Pharma Co Ltd
  • Pulmatrix Inc
  • RDS2 Solutions Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Regenasome Pty Ltd
  • Rejuvenation Technologies Inc
  • Reviva Pharmaceuticals Inc
  • Ribomic Inc
  • Roivant Sciences Ltd
  • Saje Pharma LLC
  • Samumed LLC
  • Segue Therapeutics LLC
  • Shionogi & Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Silurian Pharmaceuticals Inc
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • SynDevRx Inc
  • Taiho Pharmaceutical Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • Telocyte LLC
  • Theravance Biopharma Inc
  • TiumBio Co Ltd
  • TRACON Pharmaceuticals Inc
  • Translate Bio Inc
  • Unity Biotechnology Inc
  • Vectus Biosystems Ltd
  • Vicore Pharma AB
  • X-Rx Inc
  • Xfibra Inc
  • Yungjin Pharm Co Ltd
  • Zai Lab Ltd
Note: Product cover images may vary from those shown
Adroll
adroll